Inner Salt (e.g., Betaine, Etc.) Patents (Class 514/77)
-
Publication number: 20120258061Abstract: A skin care product comprising from about 0.001% to about 10% of a retinoid in combination with 0.0001% to about 50% of at combination of retinoid hoosters.Type: ApplicationFiled: June 21, 2012Publication date: October 11, 2012Applicant: CONOPCO, INC., D/B/A UNILEVERInventors: Stewart Paton Granger, Ian Richard Scott, Robert Mark Donovan, Susanne Teklits Iobst, Lisa Licameli
-
Publication number: 20120238527Abstract: The present invention relates to an organophosphonium derivative of the mean general formula (1), where n is a number comprised between 4 and 20, preferably between 5 and 10, m is a number between 0 and 10, preferably between 0 and 1, and Y is an anion. The invention also relates to a method for preparing same, and to a method for controlling the growth of bacterial biomass in an aqueous system, including adding to said aqueous system or contacting said aqueous system with an efficient amount of an uncoupling agent selected from an organophosphonium derivative as defined above.Type: ApplicationFiled: September 8, 2010Publication date: September 20, 2012Applicant: RHODIA OPERATIONSInventors: Philippe Marchal, Vincent Schanen, Stephane Carret-Troncy, Mickael Berard, Luc Louvel, Agnes Pilas-Begue
-
Publication number: 20120232034Abstract: Disclosed herein are vesicular formulations that include one or more phospholipids and one or more surfactants and in certain embodiments the use of such formulations for the delivery of fatty acids for the treatment of disorders such as, fatty acid metabolic disorders, including essential fatty acid deficiency; pain or inflammation or osteoarthritis, more specifically for the treatment of deep tissue pain; asthma, bronchospasm, atherothrombatic cardiovascular disorders, avenous thrombatic disorders, inflammatory dermatoses disorders (e.g., atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrheic eczema, and acne vulgaris), and dysmenorrhea.Type: ApplicationFiled: August 20, 2010Publication date: September 13, 2012Inventors: Henk-Andre Kroon, William Henry
-
Publication number: 20120208783Abstract: It is intended to find novel pharmaceutical use of sphingomyelin and to provide preventive or therapeutic agents for various diseases as well as a food and drink product and feed comprising any of these agents. The present invention provides a pharmaceutical agent which contains sphingomyelin as an active ingredient and is any of the following agents: 1) a sialomucin secretion promoter, 2) an agent for preventing drunken sickness (hangover), 3) an antiallergic agent, 4) an antioxidant, 5) an agent for defending against infection, 6) a hair growth agent, 7) a therapeutic agent for demyelinating disease, 8) an anti-pigmentation agent, 9) an anti-inflammatory agent, and 10) an agent for improving learning ability. The present invention also provides a food and drink product or feed, characterized by comprising the agent. It is preferred that the sphingomyelin should be derived from milk.Type: ApplicationFiled: January 10, 2012Publication date: August 16, 2012Applicant: SNOW BRAND MILK PRODUCTS CO., LTD.Inventors: Ken Kato, Susumu Miura, Leo Tanaka, Hiroshi Ueno, Noriko Ueda, Yuko Haruta, Toshimitsu Yoshioka
-
Publication number: 20120157396Abstract: Applicants claim the use of a pyrazine compound of formula I: or a salt thereof, for treating or preventing leishmaniases, and diseases and disorders caused by Trypanosoma cruzi or Trypanosoma brucei, and for inducing immunostimulation.Type: ApplicationFiled: November 21, 2011Publication date: June 21, 2012Applicants: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, UNITED STATES GOVERMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIR, CORNELL UNIVERSITYInventors: John T. WELCH, Susana MENDEZ, Michael H. CYNAMON
-
Publication number: 20120135087Abstract: The present invention relates to topical compositions containing choline alfoscerate for use in maintaining and restoring the integrity of the mucous membranes.Type: ApplicationFiled: March 11, 2011Publication date: May 31, 2012Applicant: RICERFARMA S.R.L.Inventor: Michele Giuseppe Di Schiena
-
Publication number: 20120128762Abstract: The present invention provides pharmaceutical compositions and methods for the instillation of lipid vehicles comprised of liposomes containing sphingomyelin or sphingomyelin metabolites to prevent, manage, ameliorate and/or treat disorders involving neuropathic pain and aberrant muscle contractions, such as what occurs in bladder hyperactivity disorders such as interstitial cystitis (IC) in animals or humans in need thereof. Also provided is a liposome-based delivery of drugs, e.g., antibiotics, pain treatments and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system and other organs or body systems. In particular, liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin and toxins, such as botulinum toxin is provided for the treatment of bladder conditions, including pain, inflammation, incontinence and voiding dysfunction.Type: ApplicationFiled: January 13, 2012Publication date: May 24, 2012Inventors: Michael B. Chancellor, Pradeep Tyagi, Matthew O. Fraser, Yao-Chi Chuang, William C. de Groat, Leaf Huang, Naoki Yoshimura
-
Publication number: 20120129808Abstract: The present invention is a blood coagulation reaction inhibitor comprising phosphatidylserine, phosphatidylcholine, and phosphatidylethanolamine. The present invention is also a thrombin generation inhibitor comprising phosphatidylserine, phosphatidylcholine, and phosphatidylethanolamine. The blood coagulation reaction inhibitor and the thrombin generation inhibitor of the present invention are useful as an antithrombotic agent, a clinical laboratory test reagent for the blood coagulation-fibrinolysis system, and the like.Type: ApplicationFiled: June 12, 2008Publication date: May 24, 2012Applicant: SHINO-TEST CORPORATIONInventor: Tomohide Tsuda
-
Publication number: 20120114637Abstract: Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are ophthalmic formulations that deliver a variety of therapeutic agents, including but not limited to rapamycin (sirolimus), analogs thereof (rapalogs) or other mTOR inhibitors, to a subject for an extended period of time. The ophthalmic formulations may be placed in an aqueous medium of a subject, including but not limited to intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer a therapeutic agent to treat or prevent age-related macular degeneration, macular edema, diabetic retinopathy, uveitis, dry eye, or a hyperpermeability disease in a subject.Type: ApplicationFiled: May 4, 2010Publication date: May 10, 2012Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Thierry Nivaggioli, David A. Weber, Philippe JM Dor, Philip Reilly
-
Publication number: 20120115814Abstract: The inventions relates to a liquid pharmaceutical form containing an active ingredient alkylphosphocholines and a co-solvent system. The co-solvent system is mixture from hexylene glycol, propylene glycol, diethylene glycol monoethyl ether and water. The pharmaceutical form having a pH value in the range of 4 to 6, which if it is necessary can be achieved by adding a pH adjuster. The composition has a good storage stability and it is suitable for local application on the different organs of the body. The inventions relates also to a method for producing the same pharmaceutical form.Type: ApplicationFiled: July 9, 2009Publication date: May 10, 2012Applicant: EXPERGEN DRUG DEVELOPMENT GMBHInventor: Paul Meng
-
Publication number: 20120108546Abstract: A synergistic antimicrobial composition comprising: (a) a hydroxymethyl-substituted phosphorus compound selected from the group consisting of tetrakis(hydroxymethyl)phoshponium salts and tris(hydroxymethyl)phosphine; and (b) tris(hydroxymethyl)nitromethane.Type: ApplicationFiled: June 17, 2010Publication date: May 3, 2012Applicant: Dow Global Technologies Inc.Inventor: Bei Yin
-
Publication number: 20120107300Abstract: Cannabinoid compositions and methods of administering said cannabinoid compositions are disclosed. The cannabinoid compositions disclosed herein include compounds which have been strategically selected to eliminate, or least mitigate, one of the negative side effects associated with consuming cannabinoids. A daytime formula includes compounds aimed at nullifying the negative side effects that cannabinoid consumption has on a patient's daily operations and activities. A nighttime formula includes compounds aimed at nullifying the negative side effects that cannabinoid consumption has a patient's sleep.Type: ApplicationFiled: November 1, 2010Publication date: May 3, 2012Inventor: Jeffrey Nathan Schirripa
-
Publication number: 20120077780Abstract: The present disclosure relates to a method of inhibiting a fat accumulation for a fat cell in a subject, which includes administering a fat accumulation inhibitor for a fat cell which includes a milk-derived phospholipid as an active ingredient to the subject. The present disclosure also relates to a method of inhibiting a visceral fat accumulation in a subject, which includes administering the visceral fat accumulation inhibitor which includes a sphingosine-containing phospholipid as an active ingredient to the subject. The present disclosure also relates to a method of accelerating increase and/or inhibiting decrease of an adiponectin concentration in blood, which includes administering an agent which includes a sphingosine-containing phospholipid as an active ingredient to the blood. The present disclosure also relates to a method of inhibiting a fat accumulation for a fat cell in a subject, which includes administering a milk-derived phospholipid to a subject.Type: ApplicationFiled: September 22, 2011Publication date: March 29, 2012Inventors: Reo Tanaka, Tomoyuki Isogai, Yuko Haruta, Susumu Miura, Ken Kato, Toshimitsu Yoshioka, Hiroshi Kawakami, Satoshi Higurashi, Hiroaki Matsuyama
-
Patent number: 8138200Abstract: The invention includes compositions and methods useful for treatment of a virus infection in a mammal by double-targeting the virus (i.e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus replication. The compositions of the invention include compounds which comprise a phosphocholine moiety covalently conjugated with one or more antiviral agents (e.g. nucleoside analogue, protease inhibitor, etc.) to a lipid backbone. The invention also includes pharmaceutical compositions and kits for use in treatment of a virus infection in mammals. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention, in an amount effective to treat the infection, to a mammal infected with a virus. Additionally, the invention includes compositions and methods useful for combating a cancer in a mammal and for facilitating delivery of a therapeutic agent to a mammalian cell.Type: GrantFiled: December 2, 2009Date of Patent: March 20, 2012Assignees: Wake Forest University, University of North Carolina-Chapel HillInventors: Louis S. Kucera, Ronald A. Fleming, Khalid S. Ishaq, Gregory L. Kucera, Susan L. Morris-Natschke
-
Publication number: 20120065167Abstract: The invention relates to the use of domperidone or a pharmaceutically acceptable salt thereof at low doses to prevent and/or treat a disease associated with an alteration of the immune response such as Leishmaniosis.Type: ApplicationFiled: March 30, 2010Publication date: March 15, 2012Applicant: LABORATORIOS DEL DR. ESTEVE S.A.Inventors: David Sabate Elias, Josep M. Homedes Beguer, Pablo Gomez Ochoa
-
Patent number: 8106032Abstract: The invention relates to methods of treating viral infections, and in particular hepatitis B virus. The method comprises administering to a subject in need of such treatment an infection-controlling amount of a phospholipid or phospholipid derivative to inhibit the activity of the viral infection.Type: GrantFiled: October 31, 2007Date of Patent: January 31, 2012Assignees: Wake Forest University, University of North Carolina at Chapel HillInventors: Louis S. Kucera, Susan L. Morris-Natschke, Khalid S. Ishaq
-
Publication number: 20110300093Abstract: The present invention relates to a cosmetic composition that includes an amphiphilic zwitterionic copolymer. The amphiphilic zwitterionic copolymer can particularly be used for imparting rheological properties, in particular a beneficial texture, to said composition and/or to the foam resulting from said composition.Type: ApplicationFiled: October 8, 2009Publication date: December 8, 2011Applicant: Rhodia OperationsInventors: Denis Bendejacq, Chi-Thanh Vuong
-
Publication number: 20110294745Abstract: The present invention relates to a solution containing at least one water-miscible biocompatible solvent and a lipophilic substance dissolved therein, wherein upon contact with aqueous body fluid the dissolved lipophilic substance is precipitated out of the solution in the form of nanoparticles and a nanosuspension is formed.Type: ApplicationFiled: November 27, 2009Publication date: December 1, 2011Applicant: UNIVERSITÄT REGENSBURGInventors: Achim Göpferich, Christoph Luschmann
-
Publication number: 20110293588Abstract: A combination of chemical agents reduces reductive stress by limiting the accumulation of high-energy electrons potentially available to the electron transport chain. A method of metabolic uncoupling therapy comprises: analyzing a specific physiologic process involving reductive stress; identifying a plurality of MUT agents that modulate metabolic pathways by influencing electron flux; and formulating a combination of MUT agents that limits the accumulation of high-energy electrons potentially available to the electron transport chain.Type: ApplicationFiled: August 4, 2011Publication date: December 1, 2011Inventor: Edward Larry McCleary
-
Publication number: 20110275598Abstract: The use of proanthocyanidin A2 and of its complexes with phospholipids for the reshaping treatment of the breast and the anti-age treatment of the neck and the décolleté is described.Type: ApplicationFiled: January 27, 2010Publication date: November 10, 2011Applicant: DERMOGYN SRLInventors: Carlo Felice Fornada, Alessandro Mazzetti, Stefano Togni
-
Publication number: 20110268811Abstract: A composition and method which improves blood lipid profiles and optionally reduces low density lipoprotein (LDL) per-oxidation in humans by administering a therapeutic amount of a composition comprising krill oil in combination with astaxanthin or a mixture of fish oil derived, choline based, phospholipid bound omega-3 fatty acid mixture including phospholipid bound polyunsaturated EPA and DHA. In one embodiment, the krill oil is derived from Euphasia spp., comprising Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) fatty acids in the form of triacylglycerides and phospholipids. The krill oil includes at least 10% EPA and 5% DHA, of which greater than 50% are in the form of phospholipids and the 1-4000 mg of krill oil per daily dose is delivered.Type: ApplicationFiled: April 25, 2011Publication date: November 3, 2011Applicant: U.S. Nutraceuticals, LLC d/b/a Valensa InternationalInventors: John A. MINATELLI, W. Stephen Hill, Rudi E. Moerck
-
Publication number: 20110263531Abstract: The present invention relates of the use of certain inner ionic (zwitter ionic) phospholipids, phosphonolipids and phosphate derivatives for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of an immunological disorder related to mast cell sensitization and/or activation. Preferred in this context are Edelfosine, Miltefosine and Perifosine. In a particularly preferred embodiment, the present invention relates to the use of Miltefosine for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of allergic diseases, in particular acute hyperallergic diseases, like asthma, atopic dermatitis and mastocytosis.Type: ApplicationFiled: July 6, 2011Publication date: October 27, 2011Inventors: Tobias BRAXMEIER, Tim FRIEDRICHSON, Gary JENNINGS
-
Publication number: 20110237548Abstract: A composition and method of retarding and ameliorating eye diseases and injuries is disclosed. The method comprises administering a synergistic mixture of certain carotenoids, including the carotenoid astaxanthin, with phospholipid and triglyceride bound EPA and DHA derived from omega choline, in which said omega choline contains at least 30% total phospholipids, in a therapeutically effective amount to prevent, retard or treat eye central nervous system diseases or injuries, such as age-related macular degeneration, cataract, dry eye syndrome due to glandular inflammation and other central nervous system degenerative diseases, photic injury, ischemic diseases, and inflammatory diseases.Type: ApplicationFiled: May 24, 2011Publication date: September 29, 2011Applicant: U.S. Nutraceuticals, LLC d/b/a Valensa InternationalInventors: John A. MINATELLI, W. Stephen Hill, Rudi E. Moerck
-
Publication number: 20110236506Abstract: Pharmaceutical combination containing lipoic acid and hydroxycitric acid as active ingredients. The present invention relates to a novel pharmaceutical combination and to the use thereof for producing a medicament having an antitumor activity. According to the invention, this combination comprises, as active ingredients: lipoic acid or one of the pharmaceutically acceptable salts thereof; and hydroxycitric acid or one of the pharmaceutically acceptable salts thereof. Said active ingredients being formulated together or separately for a conjugated, simultaneous or separate use.Type: ApplicationFiled: May 3, 2011Publication date: September 29, 2011Applicants: BIOREBUSInventors: Laurent SCHWARTZ, Adeline GUAIS-VERGNE
-
Publication number: 20110223246Abstract: Medicaments and therapeutic compositions contain (1) phospholipids having 4,7,10,13,16,19-docosahexaenoic acid covalently bound thereto and (2) at least one omega-3 polyunsaturated fatty acid, or at least one pharmaceutically acceptable omega-3 polyunsaturated fatty acid derivative or mixtures thereof, wherein about 25% of the total 4,7,10,13,16,19-docosahexaenoic acid moieties in the composition are covalently bound to phospholipids, and wherein components (1) and (2) are present in amounts effective to support overall neurological health in a subject.Type: ApplicationFiled: March 1, 2011Publication date: September 15, 2011Inventor: Joar Opheim
-
Publication number: 20110217262Abstract: A method of treating an ocular surface disorder in a subject in need of such treatment is provided. The method includes exposing conjunctival tissue of the subject to an effective amount of a vasopermeability agent that increases conjunctival vascular permeability. In some embodiments, the agent is a nitric oxide donor, which may be in a sustained release form. A method of screening a substance for treating an ocular surface disorder is also provided.Type: ApplicationFiled: March 7, 2011Publication date: September 8, 2011Inventors: Julia A. Kornfield, Robert H. Grubbs, Choon Woo Lee, Daniel Schwartz, Phoebe Lin, Keith Duncan
-
Publication number: 20110217374Abstract: Disclosed is a pharmaceutical composition simultaneously having a rapid acting property and a long-acting property, comprising a sustained-release part coated with a water-insoluble polymer on the surface, comprising a first active pharmaceutical ingredient, at least one release control base selected from the group consisting of water-insoluble polymer, and water-soluble viscous polymer, and a pharmaceutically acceptable carrier; and, an immediate release part comprising a second active pharmaceutical ingredient and a pharmaceutically acceptable carrier.Type: ApplicationFiled: May 16, 2011Publication date: September 8, 2011Applicant: YUNGJIN PHARM. CO., LTD.Inventors: Dong-Joon OH, Byoung-Ki Kim, Byung-Kwan Moon, Ji-Seok Yoo, Dae-Hee Shin, Byung-Hwan Ryoo
-
Publication number: 20110212921Abstract: Disclosed herein are formulations and methods of manufacture of compounds of formula (E): wherein X and Y independently represent leaving groups and A+ is an ammonium cation.Type: ApplicationFiled: July 30, 2009Publication date: September 1, 2011Applicant: ZIOPHARM ONOCOLOGY, INC.Inventors: Frank Walter Waligora, John C. Amedio
-
Publication number: 20110207703Abstract: Novel oxidized lipids are provided herein, as well as methods for producing same, and uses thereof in treating or preventing an inflammation associated with endogenous oxidized lipids and related conditions.Type: ApplicationFiled: November 5, 2009Publication date: August 25, 2011Applicant: Vascular Biogenics Ltd.Inventors: Eti Kovalevski-Ishai, Zeev Ziniuk, Gideon Halperin, Itzhak Mendel, Erez Feige, Niva Yacov, Eyal Breitbart
-
Publication number: 20110195061Abstract: Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA wither alone or in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.Type: ApplicationFiled: April 4, 2011Publication date: August 11, 2011Applicant: U.S. Nutraceuticals, LLC d/b/a Valensa InternationalInventors: John A. MINATELLI, W. Stephen Hill, Rudi E. Moerck
-
Publication number: 20110171195Abstract: Methods and compositions are provided for treating a urinary tract infection (UTI). The methods involve administering to a subject in need thereof a cAMP elevator or agent that mimics cAMP, particularly a labdane diterpene such as forskolin or a derivative or analog thereof in a therapeutically effective amount to treat a UTI. The methods may further include administration of at least one cAMP elevator in combination with one or more additional active compounds from other classes of therapeutic agents, such as antimicrobial agents or cholesterol lowering drugs. Compositions of the invention include pharmaceutical compositions and kits for treating a UTI in a subject in need thereof that include therapeutically effective amounts of at least two cAMP elevators, particularly where one of the cAMP elevators is a labdane diterpene such as forskolin or a derivative or analog thereof.Type: ApplicationFiled: June 12, 2008Publication date: July 14, 2011Applicant: Duke UniversityInventors: Soman N. Abraham, Brian L. Bishop, Matthew J. Duncan, K. Ranga Rama Krishnan, Jeongmin Song, Guojie Li, David A. Zaas
-
Publication number: 20110160161Abstract: The invention relates to concentrated therapeutic phospholipid compositions; methods for treating or preventing diseases associated with cardiovascular disease, metabolic syndrome, inflammation and diseases associated therewith, neurodevelopmental diseases, and neurodegenerative diseases, comprising administering an effective amount of a concentrated therapeutic phospholipid composition.Type: ApplicationFiled: October 29, 2010Publication date: June 30, 2011Applicant: ACASTI PHARMA, INC.Inventors: Fotini Sampalis, Henri Harland
-
Publication number: 20110152218Abstract: The present invention provides phospholipid in a crystalline form, a method for its preparation, compositions comprising it and its use in the treatment of damaged tissue.Type: ApplicationFiled: March 4, 2009Publication date: June 23, 2011Inventor: Derek Woodcock
-
Publication number: 20110150968Abstract: A strip, which is both edible and dissolvable, is provided comprising a film and a dosage of at least 2% of the reference daily intake (RDI) of at least one dietary supplement for malnutrition or to prevent/treat alcohol induced hangovers. A method for treating malnutrition and/or preventing and treating alcohol-induced hangovers using a dissolvable orally administered strip.Type: ApplicationFiled: June 18, 2010Publication date: June 23, 2011Inventor: Alessandra Grassi
-
Patent number: 7939683Abstract: Phospholipid-analogous compounds of the general formula (I) in which A is where R1 and R2 are, independently of one another, hydrogen, a saturated or unsaturated acyl or alkyl radical which can optionally be branched or/and substituted, where the total of the carbon atoms in the acyl and alkyl is 16 to 44 carbon atoms, s is an integer from 0 to 8, c is a radical of a primary or secondary alcohol of the formula RO—, where R is a saturated or unsaturated alkyl radical, mainly with cis double bond, of from 12 to 30 carbon atoms, n is an integer from 2 to 8, R3— a can be 1,2-dihydroxypropyl or b can be alkyl with 1 to 3 carbon atoms when z is >0 or c can be alkyl with 1 to 3 carbon atoms when n?2, and z=0, m is 1 or 2, x is an integer from 0 to 8, y is 1 for z=1 to 5 or is 1 to 4 for z=1, z is an integer from 0 to 5, are novel and are suitable as liposome constituents, solubilizers and pharmaceuticals.Type: GrantFiled: September 28, 2009Date of Patent: May 10, 2011Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.Inventor: Hans-Jörg Eibl
-
Publication number: 20110097350Abstract: Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders, as well as inflammatory disorders, immune mediated diseases, autoimmune diseases and proliferative disorders, are provided. In addition, methods of synthesizing etherified and esterified oxidized phospholipids and of using same for preventing and treating atherosclerosis and other related disorders are also provided.Type: ApplicationFiled: January 6, 2011Publication date: April 28, 2011Applicant: Vascular Biogenics Ltd.Inventors: Dror HARATS, Jacob George, Gideon Halperin, Niva Yacov, Eti Kovalevski-Ishai
-
Publication number: 20110064660Abstract: The invention generally relates to novel deuterated phospholipid compounds, compositions comprising these compounds, and their use in a variety of cancer therapy and diagnostic applications.Type: ApplicationFiled: September 10, 2010Publication date: March 17, 2011Inventors: Anatoly Pinchuk, Jamey P. Weichert, Marc Longino, William R. Clarke
-
Publication number: 20110064661Abstract: The present invention provides phospholipid ether and alkyl phospholipid compounds and their combinations with other cancer therapy agents. More specifically, the invention relates to the use of phospholipid ether compounds comprising a “cold” isotope of iodine, e.g. 127I, or H, for treating cancer and combinations of phospholipid compounds comprising radioactive (i.e., “hot”) and non-radioactive (i.e., “cold”) isotopes of iodine.Type: ApplicationFiled: September 10, 2010Publication date: March 17, 2011Inventors: Anatoly Pinchuk, Marc Longino, Jamey P. Weichert, William R. Clarke, Abram M. Vaccaro, Irawati Kandela
-
Publication number: 20110065670Abstract: A skin beautifier contains sphingomyelin, which is a phospholipid, as an effective ingredient. In addition, skin-beautifying food or feed contains sphingomyelin as an effective ingredient. The present invention provides a skin beautifier and skin-beautifying food or feed supplying effects on beauty, such as skin-moisturizing and protecting effects, skin-roughness-preventing and improving effects, and a wrinkle-preventing effect, by oral ingestion thereof.Type: ApplicationFiled: November 17, 2010Publication date: March 17, 2011Applicant: SNOW BRAND MILK PRODUCTS CO., LTD.Inventors: Ken Kato, Noriko Ueda, Susumu Miura, Toshimitsu Yoshioka
-
Publication number: 20110044969Abstract: The invention provides an antimicrobial agent for use in the treatment of a Campylobacter species which has colonised the crop of a bird, wherein the bird is exposed to said antimicrobial agent one or more times and products for carrying out the same.Type: ApplicationFiled: February 9, 2009Publication date: February 24, 2011Applicant: NOFIMA MAT ASInventors: Knut Rudi, Magne Kaldhusdal, John Nordal
-
Publication number: 20110045073Abstract: The present invention relates to controlled release composition for preventing and/or treating microbial infections in the oral cavity of a subject, said composition comprising a controlled delivery matrix which matrix has releasably associated therewith an amount of between 0.000009 and 5 wt % of a sphingolipid, wherein the composition provides a sphingolipid-release-profile in the oral cavity of a subject, wherein said release-profile is maintained for between 15 seconds and 24 hours and wherein said release-profile provides for a concentration of said sphingolipid in the saliva of said subject of between 20 ?mole/L and 250 ?mole/L.Type: ApplicationFiled: February 19, 2009Publication date: February 24, 2011Applicant: INNOPACT B.V.Inventor: Peter Frank Ekhart
-
Publication number: 20110033523Abstract: The invention relates to the use of microvesicles (MVs) derived from stem cells for preparing a medicament for the endo/epithelial regeneration of damaged tissues or organs and/or for inhibiting the apoptosis induced by cytostatic agents. The stem cell from which the microvesicles are obtained is preferably selected from the group consisting of endothelial progenitor cells (EPCs), mesenchimal stem cells (MSCs), renal progenitors CD1 33+, adult human liver stem cells (HLSC) and any combination thereof. The microvesicles may be used in both in vitro and in vivo applications, such as for example the regeneration of damaged tissues or organs and the treatment of renal injury and hepatic injury, particularly acute renal failure (ARF) and acute hepatic failure (AHF).Type: ApplicationFiled: October 29, 2007Publication date: February 10, 2011Applicant: FRESENIUS MEDICAL CARE DEUTSCHLAND G.m.b.H.Inventors: Vincenzo Cantaluppi, Maria Chiara Deregibus, Giovanni Camussi
-
Publication number: 20110028421Abstract: The invention relates to the use of alkylphosphocholines in combination with antimetabolites for the treatment of multiple myeloma, colon cancer or renal cancer. Preferred alkylphosphocholines are described by the Formula II. A particularly effective treatment includes administering a combination of perifosine and capecitabine.Type: ApplicationFiled: March 31, 2010Publication date: February 3, 2011Applicant: AEterna Zentaris GmbHInventors: Jürgen Engel, Eckhard Günther, Herbert Sindermann, Babette Aicher
-
Publication number: 20110015154Abstract: This document provides methods and materials related to regulating inflammatory pathways. For example, compositions and kits containing two or more of an anticholinesterase compound, a choline compound, and a carnitine compound and methods for using the compositions and kits described herein to support acetylcholine function to regulate one or more inflammatory pathways are provided.Type: ApplicationFiled: July 20, 2010Publication date: January 20, 2011Inventors: Gottfried H. Kellermann, Michael J. Bull
-
Publication number: 20110003773Abstract: Described herein are methods for treating lack of hair growth or a reduction or loss of existing hair by stimulating and/or restoring hair growth, or preventing hair loss. The methods comprise administering to a subject in need thereof a therapeutically effective amount of a fullerene.Type: ApplicationFiled: March 3, 2009Publication date: January 6, 2011Applicant: Luna Innovations IncorporatedInventors: Christopher L. Kepley, Robert P. Lenk, Stephen R. Wilson, Zhiguo Zhou
-
Publication number: 20110003772Abstract: The present invention relates to the use of sphingolipids for the preparation of a food item, a food supplement and/or a medicament for the treatment of insulin resistance, diabetes mellitus type 2 and/or metabolic syndrome. In particular, the invention relates to the use of a sphingolipid with the general formula (I): wherein Z is R3 or —CH(OH)—R3; A is sulphate, sulphonate, phosphate, phosphonate or —C(O)O—; R1 is H, hydroxyl, alditol, aldose, an alcohol, C1-C6 alkyl or amino acid; R2 is H or unsaturated or saturated (C1-C30) alkyl chain; R3 is unsaturated or saturated (C1-C30) alkyl chain; Q1 is a primary amine group (—NH2), secondary amine group (—NH—) or an amide group (—NH—CO—); and t is 0 or 1, or a precursor, a derivative or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention and/or treatment of a disorder selected from the group consisting of insulin resistance, diabetes type 2 and metabolic syndrome.Type: ApplicationFiled: September 17, 2010Publication date: January 6, 2011Inventors: Willem Ferdinand Nieuwenhuizen, Aloysius Maria Havekes, Josephus Jan Emeis
-
Publication number: 20100331280Abstract: There is provided a method of modifying vasoactivity by regulating a soluble A? pro-inflammatory pathway. Also provided is a method of modifying inflammatory reactions in microglia and neurons by regulating a soluble A? pro-inflammatory pathway. A method of treating patients with vascular disease by modifying an intracellular soluble A? pro-inflammatory pathway is also provided. A pharmaceutical composition consisting essentially of an effective amount of a soluble A? pro-inflammatory pathway regulator in a pharmaceutically effective carrier is also provided.Type: ApplicationFiled: October 20, 2009Publication date: December 30, 2010Inventors: Daniel C. Paris, Terrence C. Town, Michael J. Mullan
-
Publication number: 20100331281Abstract: We have discovered that phospholipids diundecanoyl (C11:0-C11:0) and dilauroyl (C12:0-C12:0) phosphatidylcholine (PC) act as agonists of the LRH-1 receptor. We have also shown that administration of these lipids to diabetic mice reduces blood glucose levels. On the basis of these discoveries, the present invention features compositions that include these lipids and structurally related lipids. Also featured are methods of treating metabolic disorders and inflammatory bowel disease, lowering blood glucose levels, and increasing LRH-1 receptor activity in a subject by administration of these lipids.Type: ApplicationFiled: November 17, 2008Publication date: December 30, 2010Applicant: Baylor College of MedicineInventors: David D. Moore, Jae Man Lee
-
Publication number: 20100331282Abstract: The present invention provides an antifungal agent that has excellent antifungal action, and is also superior in terms of its properties, and particularly its solubility in water and safety in an aqueous solution, and its in vivo pharmacokinetics and safety. According to the present invention, there is provided a compound represented by the following formula (I), or a salt thereof: wherein R1 represents a hydrogen atom, a halogen atom, an amino group, a C1-6 alkyl group, a C1-6 alkoxy group, or a C1-6 alkoxy C1-6 alkyl group; R2 represents a hydrogen atom, a C1-6 alkyl group, an amino group, or a di-C1-6 alkylamino group; R3 represents a hydrogen atom, a halogen atom, or a C1-6 alkyl group; and R4 represents a hydrogen atom, a halogen atom, or a C1-6 alkyl group.Type: ApplicationFiled: June 22, 2010Publication date: December 30, 2010Inventor: Masayuki MATSUKURA
-
Publication number: 20100311692Abstract: The present invention provides choline alfoscerate-containing pharmaceutical preparations which have improved storage-stability and are easily taken. The present invention also provides a method for manufacturing pharmaceutical preparations comprising choline alfoscerate, which is easy and simple and is performed by normal manufacturing equipments.Type: ApplicationFiled: February 13, 2009Publication date: December 9, 2010Applicant: CTC BIO, INC.Inventors: Bong-Sang Lee, Su-Jun Park, Do-Woo Kwon, Hong-Ryeol Jeon